Stock Code: 002370 Stock Abbreviation: Asia-Pacific Pharmaceutical Announcement No.: 2026-027 Zhejiang Asia-Pacific Pharmaceutical Co., Ltd. Announcement on Proposed Non-Distribution of Profits for 2025 The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and there are no false records, misleading statements, or major omissions.
I. Deliberation Procedures
- Board of Directors Deliberation The Eighth Board of Directors' Twelfth Meeting was held on April 23, 2026. The meeting unanimously approved the "2025 Profit Distribution Plan" with 9 votes in favor, 0 against, and 0 abstentions. The Board of Directors believes that since the retained earnings in the consolidated and parent company statements for 2025 are both negative, the conditions for distributing cash dividends are not met. To ensure the Company's normal production and operation and future development, the Company proposes not to distribute cash dividends, bonus shares, or transfer capital reserves into share capital for 2025. The 2025 profit distribution plan is based on the Company's actual situation and complies with relevant regulations such as the "Company Law," "Guiding Opinions on Cash Dividends of Listed Companies" (No. 3), and the "Articles of Association." This profit distribution plan is conducive to ensuring the normal operation of the Company's production and operation and better safeguarding the long-term interests of all shareholders.
- The current profit distribution plan needs to be submitted to the Company's 2025 Shareholders' Meeting for deliberation.
II. Basic Situation of the 2025 Profit Distribution Plan Audited by Zhengdazhiyuan (Shenzhen) Certified Public Accountants (Special General Partnership), the net profit attributable to shareholders of the listed company in 2025 was RMB 96,307,827.65, and the net profit of the parent company was RMB 13,518,557.98. As of December 31, 2025, the retained earnings in the consolidated statements were -1,690,956,707.64 yuan, and the retained earnings of the parent company were -1,635,730,764.96 yuan. Given that the retained earnings in the consolidated and parent company statements for 2025 are both negative, which does not meet the conditions for distributing cash dividends, and to ensure the Company's normal production and operation and future development, the Company's 2025 profit distribution plan is: no cash dividends, no bonus shares, and no capital reserve transfers for 2025.